FcR Therapeutics

Executive Summary

FcR Therapeutics is a Spanish biotechnology company founded in 2019, focused on developing first-in-class antibody therapies for autoimmune diseases by targeting Fc receptors on immune cells. The company's proprietary platform aims to disrupt pathological inflammation with improved safety and potency compared to current standards of care. Based in Barcelona, FcR Therapeutics operates in the biologics and nanotechnology sectors, with a pipeline targeting key autoimmune indications. While still in early preclinical stages, the company's differentiated approach addresses the unmet need for safer and more effective treatments in autoimmunity, leveraging the growing understanding of Fc receptor biology. The company is privately held with no disclosed funding, suggesting it is likely operating on limited resources or early-stage grant funding. Its success hinges on advancing lead candidates through preclinical validation and securing partnerships or financing to move toward clinical development.

Upcoming Catalysts (preview)

• 2026Preclinical proof-of-concept data release for lead antibody program30% success
• 2026Series A financing or grant award to support IND-enabling studies35% success
• TBDResearch collaboration or licensing deal with a larger pharma20% success